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ABSTRACT (243 words)  
Background: We compared survival outcomes and risk of venous thromboembolism 
(VTE) among patients with advanced and early-stage ovarian clear cell carcinoma (OCCC) 
and serous ovarian carcinoma (SOC), as well as potential links with interleukin-6 (IL-6) 
levels. 
Methods: A multicenter case-control study was conducted in 370 patients with OCCC and 
938 with SOC. In a subset of 200 cases, pretreatment plasma IL-6 levels were examined. 
Findings: Patients with advanced OCCC had the highest 2-year cumulative VTE rates 
(advanced OCCC 43.1%, advanced SOC 16.2%, early-stage OCCC 11.9%, and early-
stage SOC 6.4%, P < 0.0001) and the highest median levels of IL-6 (advanced OCCC 17.8 
pg/mL, advanced SOC 9.0 pg/mL, early-stage OCCC 4.2 pg/mL, and early-stage SOC 5.0 
pg/mL, P = 0.006). Advanced OCCC (hazard ratio [HR] 3.38, P < 0.0001), thrombocytosis 
(HR 1.42, P = 0.032), and elevated IL-6 (HR 8.90, P = 0.046) were independent predictors 
of VTE. In multivariate analysis, patients with advanced OCCC had significantly poorer 5-
year progression-free and overall survival rates than those with advanced SOC (P < 0.01), 
and thrombocytosis was an independent predictor of decreased survival outcomes (P < 
0.01). Elevated IL-6 levels led to poorer 2-year progression-free survival rates in patients 
with OCCC (50% vs. 87.5%, HR 4.89, P = 0.016) than in those with SOC (24.9% vs. 40.8%, 
HR 1.40, P = 0.07). 
Interpretation: Advanced OCCC is associated with an increased incidence of VTE and 
decreased survival outcomes, which has major implications for clinical management of 
OCCC.  
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INTRODUCTION 
Epithelial ovarian cancer comprises various histologic subtypes, including ovarian 
clear cell carcinoma (OCCC), which represents the second most common histologic 
subtype.1,2 Accumulating evidence suggests that OCCC has distinct clinical and molecular 
characteristics compared with other histologic subtypes of epithelial ovarian cancer.3,4 
Clinically, patients with advanced-stage OCCC have poorer survival outcomes than those 
with advanced-stage serous ovarian carcinoma (SOC), whereas patients with early-stage 
OCCC and SOC have similar survival outcomes.5,6 However, the reasons for this 
discrepancy and the mechanisms leading to poor survival outcomes in patients with 
advanced-stage OCCC have yet to be completely elucidated.  
Venous thromboembolism (VTE) is a relatively common complication in ovarian 
cancer and is associated with decreased survival outcomes.7,8 Epidemiologic studies have 
shown that patients with OCCC have an increased risk of VTE compared with patients with 
other histologic subtypes of epithelial ovarian cancer, and VTE adversely affects survival 
outcomes in patients with OCCC.9-11 One possible biomarker linking OCCC with the 
increased risk of VTE is the proinflammatory cytokine interleukin 6 (IL-6). OCCC is known 
to be associated with higher IL-6 expression than in other subtypes of epithelial ovarian 
cancer,12 and IL-6 is a pivotal marker of paraneoplastic thrombocytosis, which is a 
prognostic factor for decreased survival of ovarian cancer.13,14 IL-6 could directly increase 
the risk of VTE by inducing procoagulant factors or indirectly increase the risk by inducing 
thrombocytosis.15,16 However, it is unclear whether VTE events and IL-6 levels differ by 
stage of disease. The aim of our study was to compare the survival outcomes and risk of 
VTE among patients with early- and advanced-stage OCCC and SOC, as well as to 
examine the relationship of these outcomes to IL-6 levels.  
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PATIENTS AND METHODS 
Clinical information 
A large-scale multicenter international case-control study was conducted in 10 academic 
institutions, including 5 from the United States, 4 from Japan, and 1 from England. 
Institutional Review Board approval was obtained at each participating institution. 
Consecutive patients diagnosed with OCCC and SOC between January 1, 2000 and 
December 31, 2012 were identified from institutional databases. The STROBE guidelines 
for case-control studies were followed.17 All patients had primary OCCC or SOC that was 
histologically confirmed from surgical specimens obtained in cytoreductive surgery. Those 
with a mixed histologic type were excluded from our analysis. A fraction of this study 
population was used in our previous study.13 Medical records were retrospectively reviewed 
to obtain the following data: age, tumor markers, cytoreductive status, VTE characteristics, 
tumor characteristics, and survival outcomes. 
Tumor markers included CA-125 levels and the presence of thrombocytosis (based 
on platelet counts) at the time of diagnosis. The cutoff for thrombocytosis (platelet count 
≥400 ×109/L) was determined on the basis of prior work.18 Among those with recurrent or 
progressive disease, CA-125 levels and platelet counts were also collected at the time of 
first recurrence or progression. Residual tumor size at the end of cytoreductive surgery was 
grouped as >1 cm versus ≤1 cm. VTE characteristics included type of VTE (deep vein 
thrombosis [DVT], pulmonary embolism [PE], and others) and date of VTE diagnosis. 
Information for VTE was searched in both medical records and radiology reports for 
Doppler study, computed tomography scan, and lung scan. Tumor characteristics included 
histologic subtype (OCCC or SOC) and cancer stage (early or advanced) based on 
International Federation of Gynecology and Obstetrics (FIGO) criteria. Early-stage disease 
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was defined as FIGO stage I-II disease and advanced-stage disease was defined as FIGO 
stage III-IV disease.19  
For survival outcomes, we determined progression-free survival (PFS) and overall 
survival (OS). PFS was defined as the time interval between the date of ovarian cancer 
diagnosis and the date of the first recurrence or progression of disease or last follow-up if 
there was no recurrence or progression. OS was defined as the time interval between the 
date of ovarian cancer diagnosis and the date of death or last follow-up if the patient was 
still alive. OS after first recurrence or progression was also examined in the subset of 
patients who experienced recurrence or progression.  
 
IL-6 measurement 
Pretreatment plasma samples were available for consecutive patients in 2 institutions. 
Blood samples were obtained prior to surgery and centrifuged at 3,000 rotations per minute 
for 10 minutes. Plasma was collected and stored in 1-mL aliquots in a -80°C freezer until it 
was processed. Plasma levels of IL-6 were examined using a Human IL-6 Quantikine 
enzyme-linked immunosorbent assay (ELISA) Kit (R&D Systems, Minneapolis, MN), 
according to the manufacturer's instructions. The ELISA plates were read using Multiskan 
JX (ThermoFisher Scientific, Waltham, MA). All tests were done in triplicate. Written 
informed consent was obtained from each subject prior to the blood sampling.  
 
Statistical analysis 
The primary outcome of interest was the impact of stage-specific histologic subtype 
(advanced-OCCC, advanced-SOC, early-OCCC, or early-SOC) on cumulative risk of VTE 
and survival outcomes. The secondary outcomes of interest were the correlation between 
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IL-6 levels and VTE incidence and between IL-6 levels and survival outcomes, by stage-
specific histologic subtype. Continuous variables were assessed for normality distribution 
using Kolmogorov–Smirnov test, and results were expressed using mean (±standard 
deviation) or median (range) as appropriate. Statistical significance of continuous variables 
was determined using Student t-test or Mann-Whitney U-test, depending on normality. 
Median values across the 4 groups were examined using Kruskal-Wallis test. For 
categorical variables, chi-square test or Fisher exact test was used as appropriate. 
VTE is a time-dependent event after ovarian cancer diagnosis. Therefore, the 
statistical significance of cumulative risk of VTE was determined using log-rank test in 
univariate analysis. Cox proportional hazards regression modeling in multivariate analysis 
was also performed to identify independent predictors of VTE. For survival analysis, log-
rank test in univariate analysis and Cox proportional hazards regression modeling in 
multivariate analysis were used, and results were expressed as hazard ratios (HR) and 
95% confidence intervals (CI). In multivariate analysis, variables used in the final model 
were based on clinical relevance and impact in ovarian cancer; these included age (≥60 or 
<60 years), CA-125 levels (>35 or ≤35 IU/L), thrombocytosis (yes or no), residual tumor 
size (≤1 cm or >1 cm), VTE (yes or no), and stage-specific histologic subtype (advanced-
OCCC, advanced-SOC, early-OCCC, or early-SOC). Kaplan-Meier method was used to 
construct survival curves. P < 0.05 was considered statistical significant (two-tailed test). 
Statistical Package for the Social Sciences (SPSS, Inc., version 12.0, Chicago, IL) was 
used for all statistical analyses. 
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RESULTS 
Patient characteristics 
We evaluated the records of 1,308 patients with ovarian cancer for the current study. 
Although most of the 938 patients with SOC had advanced disease (n=836, 89.1%), most 
of the 370 patients with OCCC had early-stage disease (n=264, 71.4%; Table S1).  
Stage-specific characteristics are shown in Table 1. The mean age of the entire 
cohort was 58.5 years. Both the advanced-OCCC and advanced-SOC groups had a high 
proportion of patients with elevated CA-125 levels at the initial cancer diagnosis (advanced-
OCCC 96.2%, and advanced-SOC 87.0%). The advanced-SOC group had the highest 
proportion of patients with thrombocytosis at initial diagnosis (41.6%), followed by the 
advanced-OCCC group (32.1%). The advanced-SOC group had the highest proportion of 
patients with residual tumor size >1 cm at cytoreductive surgery (37.6%), followed by 
advanced-OCCC (26.4%). The median follow-up time of the entire cohort was 31.3 months, 
and there were 787 cases of recurrent or progressive disease (60.2%) and 487 deaths 
(37.2%) reported in the records. 
 
Characteristics of VTE 
There were 215 VTEs reported in the entire cohort (16.4%). DVT alone (n=102, 47.4%) 
was the most common type of VTE, followed by PE alone (n=56, 26.0%) and DVT+PE 
(n=51, 23.7%). The advanced-OCCC group had the highest incidence of any VTE (36.8%) 
among the 4 groups, as well as the highest incidence of DVT+PE (11.3%, P<0.0001, Table 
1).  
The cumulative prevalence of VTE was examined by stage-specific histologic 
subtype (Table 2). In univariate analysis, advanced-OCCC was associated with the highest 
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cumulative risk of VTE among the 4 groups (2-year cumulative VTE rates, advanced-
OCCC 43.1%, advanced-SOC 16.2%, early-OCCC 11.9%, and early-SOC 6.4%, P<0.0001, 
Fig. 1A). In addition, age ≥60 years (19.3% vs. 14.1%, P=0.009), elevated CA-125 levels 
(17.0% vs. 5.8%, P=0.003), and thrombocytosis (22.3% vs. 13.8%, P=0.0001) were 
associated with increased risk of VTE. Residual tumor size ≤1 cm at cytoreductive surgery 
showed a protective effect against VTE (13.6% vs. 20.2%, P=0.028).  
To identify independent risk factors for VTE, we performed multivariate analysis 
(Table 2). After controlling for age, CA-125 levels, thrombocytosis, cytoreductive status, 
and stage-specific histologic subtype, we found that advanced-OCCC remained an 
independent risk factor for VTE compared with advanced-SOC (HR 3.38, 95%CI 2.28-5.01, 
P<0.0001). Thrombocytosis also remained an independent risk factor for VTE (HR 1.42, 
95%CI 1.03-1.96, P=0.032).  
 
Survival analysis  
In the univariate analysis for 5-year PFS rates, age ≥60 years (24.6% vs. 38.4%), CA-125 
>35 IU/L (27.4% vs. 81.3%), thrombocytosis (15.3% vs. 40.7%), and VTE (15.7% vs. 
35.3%) were associated with decreased PFS (P<0.0001; Table 3). Five-year PFS rates 
were 13.3% for advanced-OCCC, 19.7% for advanced-SOC, 84.7% for early-OCCC, and 
66.9% for early-SOC (P<0.0001).  
In the multivariate analysis controlling for age, CA-125, thrombocytosis, 
cytoreductive status, VTE, and stage-specific histologic subtype, patients with advanced-
OCCC had poorer 5-year PFS rates than those with advanced-SOC (HR 1.45, 95%CI 1.12-
1.86, P=0.004; Table 3). Thrombocytosis (HR 1.39, 95%CI 1.18-1.64, P<0.0001) and VTE 
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(HR 1.28, 95%CI 1.04-1.58, P=0.02) also remained independent prognostic factors for 
decreased 5-year PFS rates.  
For 5-year OS rates, in the univariate analysis, age ≥60 years (44.7% vs. 58.0%), 
CA-125 >35 IU/L (49.1% vs. 90.7%), thrombocytosis (35.8% vs. 60.7%), and VTE (33.0% 
vs. 55.8%) were associated with decreased 5-year OS rates (P<0.0001; Table 4). Five-year 
OS rates were 28.2% for advanced-OCCC, 39.8% for advanced-SOC, 89.5% for early-
OCCC, and 82.1% for early-SOC (Fig 1B, P<0.0001).  
In the multivariate analysis controlling for age, CA-125, thrombocytosis, 
cytoreductive status, VTE, and stage-specific histologic subtype, those with advanced-
OCCC had poorer 5-year OS rates than those with advanced-SOC (HR 2.15, 95%CI 1.60-
2.88, P<0.0001; Table S2). In addition, thrombocytosis (HR 1.45, 95%CI 1.18-1.79, 
P=0.001) remained an independent prognostic factor for decreased 5-year OS rates. In a 
post-hoc multivariate analysis, 5-year OS rates did not differ between those with early-
OCCC and those with early-SOC (HR 0.62, 95%CI 0.27-1.39, P=0.24). 
 
Recurrent or progressive tumors 
In our cohort, 787 patients experienced recurrence or progression. Among these patients, 
prognostic factors for OS after the first recurrence or progression of the tumor were 
examined (Table 4). Patterns of CA-125 and thrombocytosis at recurrence or progression 
were distinctively different from those at the initial ovarian cancer diagnosis. Specifically, 
CA-125 levels were similar across the 4 stage-specific histologic subtype groups (P=0.38; 
Table 1). Although thrombocytosis was more common in those with advanced-SOC 
(41.6%) than in those with advanced-OCCC (32.1%) at the time of the initial cancer 
diagnosis, at the time of the first recurrence or progression, thrombocytosis was more 
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common in those with advanced-OCCC (27.0%) than in those with advanced-SOC (13.6%, 
P=0.028). Splenectomy at the time of cytoreductive surgery (n=15, 1.1%) was not 
associated with thrombocytosis at the time of the first recurrence or progression of disease 
(9.1% vs. 15.1%, P=1.0). 
The median OS duration after the first recurrence or progression was 13.0 months. 
In the multivariate analysis controlling for age, CA-125, thrombocytosis, VTE, and stage-
specific histologic subtype, thrombocytosis at the first recurrence or progression remained 
an independent prognostic factor for decreased 2-year OS rates after the first recurrence or 
progression (28.7% vs. 46.3%; HR 1.67, 95%CI 1.21-2.30, P=0.002). In addition, 
advanced-OCCC (17.0% vs. 46.3%; HR 2.68, 95%CI 1.90-3.79, P<0.0001) and early-
OCCC (29.5% vs. 46.3%; HR 2.12, 95%CI 1.30-3.44, P=0.002) remained independent 
prognostic factors for decreased 2-year OS rates after the first recurrence or progression 
compared to advanced-SOC (Table 4 and Fig. 1C). 
 
IL-6 levels 
Plasma samples were available for 200 patients in the cohort (OCCC n=38, and SOC 
n=162). The median plasma IL-6 level among these 200 patients was 7.6 pg/mL, and 85 of 
the patients (42.5%) had IL-6 levels ≥10 pg/mL. Thrombocytosis was associated with IL-6 
levels ≥10 pg/mL (66.7% vs. 27.0%; HR 5.39, 95%CI 2.91-10.0, P<0.0001). Patients with 
VTE had significantly higher IL-6 levels than those without VTE (median IL-6 levels: 14.4 vs. 
7.1 pg/mL, P=0.003).  
In a multivariate analysis controlling for age, CA-125 levels, thrombocytosis, 
cytoreductive status, and stage-specific histologic subtype, high pretreatment IL-6 levels 
remained an independent predictor of VTE compared with lower IL-6 levels (2-year 
12 
 
cumulative VTE rates, 5-19.9 vs. <5 pg/mL, 14.0% vs. 1.4%; HR 7.98, 95%CI 0.99-64.0, 
P=0.051; and ≥20 vs. <5 pg/mL, 17.1% vs. 1.4%; HR 8.90, 95%CI 1.04-76.0, P=0.046; 
Table 5).  
Across the 4 stage-specific histologic subtype groups, the advanced-OCCC group 
had the highest proportion of IL-6 levels ≥10 pg/mL (advanced-OCCC 83.3%, advanced-
SOC 47.7%, early-OCCC 15.6%, and early-SOC 27.3%, P=0.001, Fig. 1D). Similarly, the 
advanced-OCCC group had the highest median IL-6 levels among the 4 groups (advanced-
OCCC 17.8 pg/mL, advanced-SOC 9.0 pg/mL, early-OCCC 4.2 pg/mL, and early-SOC 5.0 
pg/mL, P=0.006). Similar to the results from the entire cohort, advanced-OCCC was 
associated with the highest risk of VTE across the 4 groups (2-year cumulative VTE risk: 
advanced-OCCC 40%, advanced-SOC 13.4%, early-OCCC 17.5%, and early-SOC 0%, 
P=0.039).  
Among the 200 patients in whom IL-6 levels were examined, IL-6 levels ≥10 pg/mL 
were associated with decreased 2-year PFS rates (27.4% vs. 47.6%; HR 1.58, 95%CI 
1.11-2.26, P=0.013). However, when the patients were stratified by histologic subtype, the 
magnitude of the difference was larger in those with OCCC (2-year PFS rates, IL-6 ≥10 vs. 
<10 pg/mL, 50% vs. 87.5%, HR 4.89, 95%CI 1.17-20.5, P=0.016, Fig. 1E) than in those 
with SOC (24.9% vs. 40.8%, HR 1.40, 95%CI 0.97-2.03, P=0.07, Fig. 1F). 
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DISCUSSION 
In the current study, advanced-OCCC, but not early-OCCC, was associated with a 
substantially increased risk of VTE compared with advanced-SOC. Patients with advanced-
OCCC also had the highest frequency of elevated IL-6 levels, and those with advanced-
OCCC had poorer survival outcomes than those with advanced-SOC. These findings 
suggest that the IL-6 pathway plays a pivotal role in the progression of OCCC. A proposed 
schema of the role of IL-6 in OCCC, based on our results, is shown in Figure S1. 
A recent study showed that paraneoplastic thrombocytosis contributed to poor 
outcomes in ovarian cancer. The authors showed that IL-6 stimulates hepatocytes to 
induce thrombopoietin, which further induces megakaryocytes in bone marrow to produce 
platelets.13 These IL-6–induced platelets promote tumor progression by providing platelet-
related cancer cell protection from the host immune system, providing growth factors, and 
promoting tumor angiogenesis. In our study, survival analyses showed that both advanced-
OCCC and thrombocytosis were the common prognostic factors for decreased survival 
outcomes (Table 3-4). In addition, elevated IL-6 levels were associated with thrombocytosis 
and advanced disease. These findings provide evidence for the existence of IL-6–mediated 
paraneoplastic thrombocytosis in advanced-OCCC.  
Although IL-6–mediated paraneoplastic thrombocytosis is a proposed mechanism 
for tumor progression in advanced-OCCC, our study showed that thrombocytosis was less 
common in patients with advanced-OCCC than in those with advanced-SOC (32.1% vs. 
41.6%, Table 1). This implies that the IL-6–mediated paraneoplastic thrombocytosis is 
more prominent in SOC, and there may be an alternative IL-6–related pathway that 
contributes to tumor progression in OCCC, such as a direct autocrine pathway. Recently, 
the tumor microenvironment was reported to be a source of IL-6 in certain types of 
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malignancy.20,21 Some researchers have even speculated that the tumor microenvironment 
may supply IL-6 in SOC.22 Therefore, hypothetically, there are 2 possible pathways for IL-6 
interaction in ovarian cancer: (i) direct pathway via autocrine IL-6 signaling and (ii) IL-6–
mediated indirect pathway via paraneoplastic thrombocytosis.13,22 In the IL-6 autocrine 
pathway in OCCC, downstream signaling of the IL-6 receptor is activated via the HIF1A-
STAT3 cascade and ultimately induces VEGF, a key mediator for tumor angiogenesis.12, 23, 
24 Indeed, VEGF expression in OCCC is significantly higher than in other histologic types of 
epithelial ovarian cancer.25 Collectively, our findings suggest that both direct and indirect IL-
6 pathways may lead to tumor progression in OCCC, and the direct pathway may be more 
active in OCCC. 
VTE is a common issue in OCCC.10 Quality of life in cancer patients can be 
compromised as a result of the VTE itself and from drug injections, treatment costs, and 
decreased survival outcomes. In our study, those with VTE had significantly higher levels of 
IL-6 than those who did not have VTE, and this association has not been well studied in 
cancer patients.26 In addition, VTE was associated with thrombocytosis (Table 2), which 
has recently been recognized in the oncology field.27 Our findings also showed that 
elevated IL-6 is associated with thrombocytosis, and those with advanced-OCCC had the 
highest frequency of multiple-site VTE (DVE+PE; 11.3%) compared with the other groups. 
Taken together, our findings indicate that VTE in OCCC is a clinical manifestation and 
surrogate marker of the aggressiveness of IL-6–driven tumor progression, and the 
decreased survival outcomes in those who develop VTE among OCCC patients is more 
likely from the aggressive tumor behavior than from cardiovascular collapse.  
Although overexpression of IL-6 in OCCC has been reported by various 
investigators, the exact mechanism driving IL-6 overexpression in OCCC has yet to be 
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determined.28 Although a fraction of IL-6 may come from the tumor microenvironment, a 
substantial fraction of IL-6 is speculated to come from tumor cells in OCCC given its high 
IL-6 expression. To date, ARID1A mutation (loss of function) and PIK3CA mutation (gain of 
function) have been identified as common occurrences in OCCC (40-60%).2,29  Available 
evidence suggests a possible link between the PIK3CA mutation and IL-6 overexpression. 
Specifically, the PIK3CA mutation upregulates NF-κB, which leads to IL-6–dependent 
STAT3 activation.30 Moreover, a recent pre-clinical study has shown that additional loss of 
ARID1A function in the setting of PIK3CA overexpression is a key step in pathogenesis of 
OCCC.31 Interestingly, IL-6 transcription in this OCCC model of ARID1A and PIK3CA 
mutation is found to be elevated. Therefore, it is paramount to see if this correlation seen in 
pre-clinical study also exists in human samples of OCCC by sequencing ARID1A and 
PIK3CA correlating with plasma IL-6 level.  
The unique characteristics of recurrent or progressive OCCC deserve further 
discussion. Generally, recurrent OCCC is resistant to therapy, with a response rate of 
<10%.32 This was also true in our study, and those with advanced-OCCC had poorer 2-
year OS rates after recurrence or progression than those with advanced-SOC (Table 5). 
The advanced-OCCC group had a higher proportion of patients with thrombocytosis at the 
first recurrence or progression than the other groups, and this may represent a role for 
paraneoplastic thrombocytosis in the setting of advanced-OCCC. Interestingly, 2-year OS 
rates after recurrence or progression were also shorter in those with early-OCCC than in 
those with advanced-SOC. This implies that recurrent or progressive OCCC is quite 
chemoresistant regardless of original disease status. Our study did not have information for 
chemotherapy treatment after the first recurrence or progression and therefore we were 
unable to address this question. 
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A potential limitation of our study is that this is a retrospective study that may have 
some confounding factors. For example, we did not use the standard case record form to 
capture VTE events; however, all the participating institutions are tertiary care cancer 
centers and patient follow-up is quite consistent. In addition, central pathology review to 
confirm OCCC was not performed for the study. A potential weakness of our study is that 
central histopathologic slide review was not available for grading serous tumors.33,34 
Nevertheless, in post-hoc analysis, high-grade SOC cases (n=768) were compared to CCC 
cases (Table S3-6). The results were consistent in that advanced-OCCC was significantly 
associated with increased risk of VTE (HR 3.34, 95%CI 2.23-4.99, P<0.0001), decreased 
PFS (HR 1.55, 95%CI 1.20-2.01, P=0.002), decreased OS (HR 2.19, 95%CI 1.62-2.97, 
P<0.0001), and decreased OS after the first recurrence or progression of disease (HR 2.73, 
95%CI 1.89-3.96, P<0.0001) compared to advanced high-grade SOC in multivariate 
analysis. Lastly, a relatively small sample size for IL-6 assessment may limit 
generalizability. 
In summary, our results indicate that advanced-OCCC is thrombogenic and may be 
a surrogate marker of tumor-biologically more aggressive disease. Treatment involving 
both anti-thrombotic agents and blocking of IL-6 signaling may be an attractive approach in 
advanced-OCCC. A phase II study examining the efficacy of the combination of a 
monoclonal antibody against IL-6 with siltuximab for platinum-resistant ovarian cancer 
showed that the combination had some therapeutic activity; however, this study was not 
solely for patients with OCCC.35 Statin therapy is also suggested to reduce IL-6 activity and 
VTE risk by inhibiting inflammatory cytokines, resulting in reduced cancer-related mortality. 
36,37 Currently (as of April 8, 2015), no ongoing clinical trial of a treatment targeting IL-6 for 
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OCCC has been registered at clinicaltrials.gov. Further preclinical and clinical studies are 
warranted. 
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Table 1. Patient characteristics by stage-specific histologic subtype in our cohort (n = 1,308) 
Characteristic 
No. (%) 
P-value
†
 
OCCC (n = 370) SOC (n = 938) 
Advanced Early Advanced Early 
No. of patients 106 (28.6) 264 (71.4) 836 (89.1) 102 (10.9)  
Mean age (±standard 
deviation) 
57.6 years (± 
10.2 years) 
53.1 years (± 
10.2 years) 
60.3 years (± 
11.2 years) 
58.5 years (± 
10.6 years) 
< 0.0001 
<60 years 62 (58.5) 194 (73.5) 394 (47.1) 55 (53.9)  
≥60 years 44 (41.5) 70 (26.5) 442 (52.9) 47 (46.1)  
Median CA-125 levels at 
diagnosis (range) 
358 IU/L (17-
21120 IU/L) 
59 IU/L (6-
20887 IU/L) 
841 IU/L (8-
86591 IU/L) 
223 IU/L (4-
21634 IU/L) 
< 0.0001 
≤35 IU/L 3 (2.8) 87 (33) 16 (1.9) 26 (25.5)  
>35 IU/L 102 (96.2) 167 (63.3) 727 (87) 65 (63.7)  
Unknown 1 (0.9) 10 (3.8) 93 (11.1) 11 (10.8)  
Median CA-125 levels at 
first recurrence or 
progression (range)* 
108 IU/L (7-
1019 IU/L) 
180 IU/L (6-
1320 IU/L) 
351 IU/L (4-
12957 IU/L) 
170 IU/L (5-681 
IU/L) 
0.38 
≤35 IU/L 15 (18.8) 11 (33.3) 80 (12.5) 8 (25)  
>35 IU/L 47 (58.8) 19 (57.6) 262 (40.8) 18 (56.3)  
Unknown 18 (22.5) 3 (9.1) 300 (46.7) 6 (18.7)  
Median platelet counts at 
diagnosis (range) 
336 × 10
9
/L 
(145-696 × 
10
9
/L) 
287 × 10
9
/L 
(115-834 × 
10
9
/L) 
368 × 10
9
/L (82-
979 × 10
9
/L) 
269 × 10
9
/L (97-
594 × 10
9
/L) 
< 0.0001 
<400 × 10
9
/L 71 (67) 217 (82.2) 480 (57.4) 92 (90.2)  
≥400 × 10
9
/L 34 (32.1) 43 (16.3) 348 (41.6) 9 (8.8)  
Unknown 1 (0.9) 4 (1.5) 8 (1.0) 1 (1.0)  
Median platelet counts at 
first recurrence or 
progression (range)* 
271 × 10
9
/L (54-
1329 × 10
9
/L) 
234 × 10
9
/L 
(96-739 × 
10
9
/L) 
243 × 10
9
/L (34-
1178 × 10
9
/L) 
239 × 10
9
/L 
(127-779 × 
10
9
/L) 
0.028 
<400 × 10
9
/L 46 (57.5) 26 (78.8) 287 (44.7) 23 (71.9)  
≥400 × 10
9
/L 17 (21.3) 3 (9.1) 45 (7.0) 2 (6.3)  
Unknown 17 (21.3) 4 (12.1) 310 (48.3) 7 (21.9)  
Residual tumor size after 
surgery 
    < 0.0001 
> 1 cm 28 (26.4) 3 (1.1) 314 (37.6) 8 (7.8)  
≤ 1 cm 72 (67.9) 261 (98.9) 470 (56.2) 94 (92.2)  
Unknown 6 (5.7) 0 (0) 52 (6.2) 0 (0)  
Recurrent or progressive 
disease 
    < 0.0001 
No 26 (24.5) 231 (87.5) 194 (23.2) 70 (68.6)  
Yes 80 (75.5) 33 (12.5) 642 (76.8) 32 (31.4)  
Death     < 0.0001 
No 44 (41.5) 244 (92.4) 444 (53.1) 89 (87.3)  
Yes 62 (58.5) 20 (7.6) 392 (46.9) 13 (12.7)  
Type of venous 
thromboembolism 
    < 0.0001 
None 67 (63.2) 230 (87.1) 704 (84.2) 92 (90.2)  
DVT alone 17 (16.0) 13 (4.9) 69 (8.3) 3 (2.9)  
PE alone 9 (8.5) 4 (1.5) 41 (4.9) 2 (2.0)  
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DVT + PE 12 (11.3) 14 (5.3) 21 (2.5) 4 (3.9)  
Other 1 (0.9) 3 (1.1) 1 (0.1) 1 (1.0)  
Any 39 (36.8) 34 (12.9) 132 (15.8) 10 (9.8)  
 
† The chi-square test was used for P values 
* Advanced OCCC: n = 80; early-stage OCCC: n = 33; advanced SOC: n = 642; early-stage SOC: n 
= 32. 
. Abbreviations: OCCC, ovarian clear cell carcinoma; SOC, serous ovarian carcinoma; CA-125, 
cancer antigen 125; DVT, deep vein thrombosis; PE, pulmonary embolism. 
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Table 2. Risk factors for venous thromboembolism in our cohort (n = 1,308) 
Variable 
  
No. 
 2-year 
cumulative 
rate, % 
Univariate Multivariate 
HR (95%CI) P-value
†
 HR (95%CI) P-value
†
 
Age    0.009  0.016 
<60 years 705 14.1 1  1  
≥60 years 603 19.3 1.42 (1.09-1.86)  1.46 (1.07-1.99)  
CA-125 levels    0.003  0.025 
≤ 35 IU/L 132 5.8 1  1  
> 35 IU/L 1061 17.0 2.52 (1.33-4.76)  2.38 (1.11-5.07)  
Thrombocytosis*    0.0001  0.032 
No 860 13.8 1  1  
Yes 434 22.3 1.66 (1.26-2.18)  1.42 (1.03-1.96)  
Residual tumor size 
after surgery 
   0.028  0.52 
> 1 cm 353 20.2 1  1  
≤ 1 cm 897 13.6 0.72 (0.53-0.97)  0.89 (0.63-1.27)  
Stage-specific 
histologic type 
   < 0.0001   
Advanced SOC 836 16.2 1  1  
Advanced OCCC 106 43.1 2.74 (1.92-3.92)  3.38 (2.28-5.01) < 0.0001 
Early-stage SOC 102 6.4 0.54 (0.28-1.03)  0.80 (0.38-1.68) 0.55 
Early-stage 
OCCC 
264 11.9 0.73 (0.50-1.06)  1.23 (0.77-1.95) 0.39 
 
† The log-rank test was used for univariate analysis and Cox proportional hazards regression 
modeling was used for multivariate analysis.  
* Platelet count ≥400 × 109/L. 
Abbreviations: HR, hazard ratio; CI, confidence interval; CA-125, cancer antigen 125; SOC, serous 
ovarian carcinoma; OCCC, ovarian clear cell carcinoma. 
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Table 3. Factors influencing 5-year progression-free survival (PFS) rates in our cohort (n = 
1,308) 
Variable 
 
No. 
5-year 
PFS, % 
Univariate Multivariate 
HR (95%CI) P-value
†
 HR (95%CI) P-value
†
 
Age    < 0.0001  0.35 
<60 years 705 38.4 1  1  
≥60 years 603 24.6 1.45 (1.26-1.67)  1.08 (0.92-1.27)  
CA-125 levels    < 0.0001  0.002 
≤35 IU/L 132 81.3 1  1  
>35 IU/L 1061 27.4 6.95 (4.40-11.0)  2.29 (1.35-3.88)  
Thrombocytosis*    < 0.0001  < 0.0001 
No 860 40.7 1  1  
Yes 434 15.3 2.09 (1.80-2.41)  1.39 (1.18-1.64)  
Residual tumor size 
after surgery 
   < 0.0001  < 0.0001 
> 1 cm 353 8.5 1  1  
≤ 1 cm 897 43.3 0.35 (0.30-0.41)  0.64 (0.54-0.76)  
VTE    < 0.0001  0.02 
No 1093 35.3 1  1  
Yes 215 15.7 1.78 (1.49-2.12)  1.28 (1.04-1.58)  
Stage-specific 
histologic type 
   < 0.0001   
Advanced SOC 836 19.7 1  1  
Advanced OCCC 106 13.3 1.31 (1.04-1.66)  1.45 (1.12-1.86) 0.004 
Early-stage SOC 102 66.9 0.23 (0.16-0.32)  0.36 (0.24-0.55) < 0.0001 
Early-stage OCCC 264 84.7 0.09 (0.06-0.13)  0.14 (0.10-0.21) < 0.0001 
 
† The log-rank test was used for univariate analysis and Cox proportional hazards regression 
modeling was used for multivariate analysis.  
* Platelet count ≥400 × 109/L. 
Abbreviations: HR, hazard ratio; CI, confidence interval; CA-125, cancer antigen 125; VTE, venous 
thromboembolism; SOC, serous ovarian carcinoma; OCCC, ovarian clear cell carcinoma. 
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Table 4. Factors influencing overall survival (OS) after recurrence or progression in a 
portion of our cohort (n = 787) 
Variable 
  
No. 
 2-year OS 
rate after 
recurrence, % 
Univariate Multivariate 
HR (95%CI) P-value
†
 HR (95%CI) P-value
†
 
Age    0.046  0.15 
<60 years 384 46.8 1  1  
≥60 years 403 39.4 1.20 (1.00-1.44)  1.21 (0.94-1.56)  
CA-125 levels*    < 0.0001  < 0.0001 
≤35 IU/L 114 64.0 1  1  
>35 IU/L 346 41.8 1.97 (1.43-2.72)  2.02 (1.44-2.84)  
Thrombocytosis*    < 0.0001  0.002 
No 382 49.3 1  1  
Yes 67 28.7 2.00 (1.47^2.71)  1.67 (1.21-2.30)  
VTE    0.05  0.97 
No 625 45.3 1  1  
Yes 162 35.2 1.24 (1.00-1.54)  1.01 (0.74-1.37)  
Stage-specific 
histologic subtype 
   < 0.0001   
Advanced SOC 642 46.3 1  1  
Advanced 
OCCC 
80 17.0 2.24 (1.70-.94)  2.68 (1.90-3.79) < 0.0001 
Early-stage SOC 32 61.3 0.59 (0.33-1.05)  0.84 (0.44-1.60) 0.60 
Early-stage 
OCCC 
33 29.5 1.20 (0.77-1.89)  2.12 (1.30-3.44) 0.002 
 
† The log-rank test was used for univariate analysis and Cox proportional hazards regression 
modeling was used for multivariate analysis.  
* CA-125 and platelet counts were measured at the time of first recurrence or progression of 
disease. 
Abbreviations: HR, hazard ratio; CI, confidence interval; CA-125, cancer antigen 125; VTE, venous 
thromboembolism; SOC, serous ovarian carcinoma; OCCC, ovarian clear cell carcinoma. 
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Table 5. Interleukin-6 (IL-6) and risk of venous thromboembolism in a portion of our cohort 
(n = 200)  
Variable 
  
No. 
 2-year 
cumulative 
rate, % 
Univariate Multivariate 
HR (95% CI) P value HR (95% CI) P value 
Age    0.57  0.78 
<60 years 99 12.4 1  1  
≥60 years 101 9.1 0.78 (0.33-1.86)  0.87 (0.34-2.22)  
CA-125 levels    0.19  0.95 
≤35 IU/L 15 0.0 1  1  
>35 IU/L 185 11.6 22.7 (0.02-28568)  na  
Thrombocytosis*    0.028  0.31 
No 122 7.0 1  1  
Yes 78 16.7 2.58 (1.07-6.22)  1.65 (0.63-4.33)  
Residual tumor size 
after surgery 
   0.96  0.84 
> 1 cm 63 11.5 1  1  
≤ 1 cm 137 10.0 1.03 (0.39-2.67)  1.11 (0.41-3.04)  
Stage-specific 
histologic subtype 
   0.039   
Advanced SOC 151 13.4 1  1  
Advanced OCCC 6 40.0 5.07 (1.13-22.7)  3.43 (0.76-15.6) 0.11 
Early-stage SOC 11 0.0 0  na 0.99 
Early-stage 
OCCC 
32 17.5 2.17 (0.77-6.13)  4.00 (1.25-12.8) 0.019 
IL-6 levels prior to 
treatment** 
   0.012   
<5 pg/mL 68 1.4 1  1  
5-19.9 pg/mL 79 14.0 9.66 (1.25-74.9)  7.98 (0.99-64.0) 0.051 
≥20 pg/mL 53 17.1 12.1 (1.53-95.5)  8.90 (1.04-76.0) 0.046 
 
The log-rank test was used for univariate analysis and Cox proportional hazards regression 
modeling was used for multivariate analysis. Abbreviations: HR, hazard ratio; CI, confidence 
interval; CA-125, cancer antigen 125; VTE, venous thromboembolism; SOC, serous ovarian 
cancer; OCCC, ovarian clear cell carcinoma; na, not available. 
*Platelet count ≥400 × 109/L. 
**IL-6 levels were grouped into lower third (1-33%ile, <5 pg/mL), mid third (34-66%ile, 5-19.9 
pg/mL), and upper third (≥67%ile, ≥20 pg/mL). 
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Figure 1. Venous thromboembolism (VTE), interleukin-6 (IL-6), and survival of ovarian 
cancer.  
28 
 
The log-rank test or chi-square test were used to generate the P values. A) Cumulative risk of 
thromboembolism after diagnosis of ovarian cancer. B) Overall survival by stage-specific histologic 
subtype. C) Overall survival after recurrence or progression by stage-specific histologic subtype. D) 
Proportion of patients with IL-6 levels ≥10 pg/mL (prior to treatment), by stage-specific histologic 
subtype. E) Progression-free survival by IL-6 level in patients with ovarian clear cell carcinoma 
(OCCC). F) Progression-free survival by IL-6 level in patients with serous ovarian carcinoma (SOC). 
Abbreviations: HR, hazard ratio.  
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Supplemental Table S1. Patient characteristics in our cohort (N = 1,308) 
 Characteristic 
No. (%) 
P value OCCC SOC 
No. of patients 370 938  
Mean age (± standard 
deviation) 
54.4 years 
(±10.4 years) 
60.1 years 
(±11.1 years) 
<0.0001 
<60 years 256 (69.2) 449 (47.9)  
≥60 years 114 (30.8) 489 (52.1)  
Median CA-125 levels at 
diagnosis (range) 
117 IU/L (6-
21120 IU/L) 
754 IU/L (4-
865591 IU/L) 
<0.0001 
≤35 IU/L 90 (24.3) 42 (4.5)  
>35 IU/L 269 (72.7) 792 (84.4)  
Unknown 11 (3.0) 104 (11.1)  
Median CA-125 levels at 
first recurrence or 
progression (range)* 
95 IU/L (6-
1320 IU/L) 
101 IU/L (4-
12957 IU/L) 
0.45 
≤35 IU/L 26 (23.0) 88 (13.1)  
>35 IU/L 66 (58.4) 280 (41.5)  
Unknown 21 (18.6) 306 (45.4)  
Median platelet counts at 
diagnosis (range) 
294 × 10
9
/L 
(115-834 × 
10
9
/L) 
353 × 10
9
/L (82-
979 × 10
9
/L) 
<0.0001 
<400 × 10
9
/L 288 (77.8) 572 (61.0)  
≥400 × 109/L 77 (20.8) 357 (38.0)  
Unknown 5 (1.4) 9 (1.0)  
Median platelet counts at 
first recurrence or 
progression (range)*  
252 × 10
9
/L 
(54-1329 × 
10
9
/L) 
242 × 10
9
/L (34-
1178 × 10
9
/L) 
0.40 
<400 × 10
9
/L 72 (63.7) 310 (46.0)  
≥400 × 109/L 20 (17.7) 47 (7.0)  
Unknown 21 (18.6) 317 (47.0)  
Stage   <0.0001 
I 225 (60.8) 57 (6.1)  
II 39 (10.5) 45 (4.8)  
III 87 (23.5) 652 (69.5)  
IV 19 (5.1) 184 (19.6)  
Residual tumor size after 
surgery 
  <0.0001 
> 1 cm 31 (8.4) 322 (34.3)  
≤ 1 cm 333 (90.0) 564 (60.1)  
Unknown 6 (1.6) 52 (5.5)  
Recurrence   <0.0001 
No 257 (69.5) 264 (28.1)  
Yes 113 (30.5) 674 (71.9)  
Death   <0.0001 
No 288 (77.8) 533 (56.8)  
Yes 82 (22.2) 405 (43.2)  
Type of venous 
thromboembolism 
  0.002 
None 297 (80.3) 796 (84.9)  
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DVT alone 30 (8.1) 72 (7.7)  
PE alone 13 (3.5) 43 (4.6)  
DVT + PE 26 (7.0) 25 (2.7)  
Other 4 (1.1) 2 (0.2)  
Any 73 (19.7) 142 (15.1)  
 
The Student t test, Mann-Whitney U test, or chi-square test were used for P values. Abbreviations: 
OCCC, ovarian clear cell carcinoma; SOC, serous ovarian cancer; CA-125, cancer antigen 125; 
DVT, deep vein thrombosis; PE, pulmonary embolism. 
* OCCC: n = 113; SOC: n = 674.
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Table S2. Factors influencing 5-year overall survival (OS) rates in our cohort (n = 1,308) 
Variable 
  
No. 
5-year 
OS, % 
Univariate Multivariate 
HR (95%CI) P-value
†
 HR (95%CI) P-value
†
 
Age    < 0.0001  0.18 
<60 years 705 58.0 1  1  
≥60 years 603 44.7 1.47 (1.23-1.76)  1.15 (0.94-1.41)  
CA-125 levels    < 0.0001  0.007 
≤35 IU/L 132 90.7 1  1  
>35 IU/L 1061 49.1 8.80 (4.37-17.7)  3.20 (1.38-7.45)  
Thrombocytosis*    < 0.0001  0.001 
No 860 60.7 1  1  
Yes 434 35.8 2.17 (1.81-2.60)  1.45 (1.18-1.79)  
Residual tumor size 
after surgery 
   < 0.0001  <0.0001 
> 1 cm 353 28.0 1  1  
≤ 1 cm 897 64.4 0.33 (0.28-0.40)  0.57 (0.46-0.70)  
VTE    < 0.0001  0.15 
No 1093 55.8 1  1  
Yes 215 33.0 1.84 (1.49-2.28)  1.22 (0.93-1.58)  
Stage-specific 
histologic type 
   < 0.0001   
Advanced SOC 836 39.8 1  1  
Advanced OCCC 106 28.2 1.83 (1.40-2.39)  2.15 (1.60-2.88) < 0.0001 
Early-stage SOC 102 82.1 0.19 (0.11-0.34)  0.33 (0.17-0.63) 0.001 
Early-stage OCCC 264 89.5 0.12 (0.08-0.19)  0.23 (0.14-0.39) < 0.0001 
 
† The log-rank test was used for univariate analysis and Cox proportional hazards regression 
modeling was used for multivariate analysis.  
* Platelet count ≥400 ×109/L. 
Abbreviations: HR, hazard ratio; CI, confidence interval; CA-125, cancer antigen 125; VTE, venous 
thromboembolism; SOC, serous ovarian cancer; OCCC, ovarian clear cell carcinoma. 
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Table S3. Risk factors for venous thromboembolism in sub-analysis (n =1,138) 
Variable 
  
No. 
 2-year 
cumulative 
rate, % 
Univariate Multivariate 
HR (95%CI) P-value
†
 HR (95%CI) P-value
†
 
Age    0.006  0.012 
<60 years 616 18.9 1  1  
≥60 years 522 26.4 1.48 (1.12-1.95)   1.51 (1.10-2.08)   
CA-125 levels    0.005  0.038 
≤ 35 IU/L 120 9.1  1  1  
> 35 IU/L 912 22.8 2.52 (1.33-4.77)   2.24 (1.05-4.79)   
Thrombocytosis*    0.002  0.23  
No 744 18.0  1  1  
Yes 380 31.8 1.55 (1.17-2.05)   1.23 (0.88-1.72)   
Residual tumor size 
after surgery 
   0.001  0.001 
> 1 cm 834 25.0  1  1  
≤ 1 cm 247 11.5 0.49 (0.33-0.75)   0.52 (0.32-0.86)   
Stage-specific 
histologic type 
      
Advanced  
HG-SOC 
701 23.6 1  1  
Advanced  
OCCC 
106 47.1 2.50 (1.74-3.59) <0.0001 3.34 (2.23-4.99) <0.0001 
Early-stage  
HG-SOC 
67 13.9 0.74 (0.39-1.41) 0.35 1.10 (0.53-2.32) 0.79 
Early-stage  
OCCC 
264 14.5 0.66 (0.45-0.97) 0.033 1.47 (0.88-2.44) 0.13 
 
† The log-rank test was used for univariate analysis and Cox proportional hazards regression 
modeling was used for multivariate analysis.  
* Platelet count ≥400 × 109/L. 
Abbreviations: HR, hazard ratio; CI, confidence interval; CA-125, cancer antigen 125; HG-SOC, 
high-grade serous ovarian cancer; OCCC, ovarian clear cell carcinoma. 
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Table S4. Factors influencing 5-year progression-free survival (PFS) rates in sub-analysis (n 
= 1,138) 
Variable 
 
No. 
5-year 
PFS, % 
Univariate Multivariate 
HR (95%CI) P-value
†
 HR (95%CI) P-value
†
 
Age    <0.0001  0.43 
<60 years 616 40.0 1  1  
≥60 years 522 25.3 1.46 (1.25-1.70)   1.07 (0.90-1.28)   
CA-125 levels    <0.0001  0.006 
≤35 IU/L 120 81.3 1  1  
>35 IU/L 912 28.8 6.90 (4.26-11.2)   2.20 (1.26-3.85)   
Thrombocytosis*    <0.0001  0.001 
No 744 42.2 1  1  
Yes 380 16.4 2.10 (1.80-2.46)   1.35 (1.13-1.62)   
Residual tumor size 
after surgery 
   <0.0001  0.059 
> 1 cm 834 22.5 1  1  
≤ 1 cm 247 74.7 0.19 (0.14-0.25)   1.24 (0.99-1.54)   
VTE    <0.0001  0.044 
No 935 37 1  1  
Yes 203 16.2 1.79 (1.49-2.15)   1.25 (1.01-1.56)   
Stage-specific 
histologic type 
      
Advanced  
HG-SOC 
701 13.3 1  1  
Advanced  
OCCC 
106 19.7 1.28 (1.01-1.62) 0.041 1.55 (1.20-2.01) 0.001 
Early-stage  
HG-SOC 
67 68.4 0.22 (0.14-0.35) <0.0001 0.34 (0.21-0.56) <0.0001 
Early-stage  
OCCC 
264 84.7 0.09 (0.06-0.13) <0.0001 0.17 (0.12-0.26) <0.0001 
 
† The log-rank test was used for univariate analysis and Cox proportional hazards regression 
modeling was used for multivariate analysis.  
* Platelet count ≥400 × 109/L. 
Abbreviations: HR, hazard ratio; CI, confidence interval; CA-125, cancer antigen 125; VTE, venous 
thromboembolism; HG-SOC, high-grade serous ovarian cancer; OCCC, ovarian clear cell 
carcinoma.
34 
 
Table S5. Factors influencing 5-year overall survival (OS) rates in sub-analysis (n =1,138) 
Variable 
  
No. 
5-year 
OS, % 
Univariate Multivariate 
HR (95%CI) P-value
†
 HR (95%CI) P-value
†
 
Age    <0.0001  0.13 
<60 years 616 57.3 1  1  
≥60 years 522 43.1 1.49 (1.23-1.79)   1.19 (0.95-1.47)   
CA-125 levels    <0.0001  0.013 
≤35 IU/L 120 89.9 1  1  
>35 IU/L 912 47.4 8.42 (4.18-17.0)   2.93 (1.26-6.80)   
Thrombocytosis*    <0.0001  0.005 
No 744 59.2 1  1  
Yes 380 35.5 2.12 (1.75-2.55)   1.37 (1.10-1.71)   
Residual tumor size 
after surgery 
   <0.0001  <0.0001 
> 1 cm 834 42.8 1  1  
≤ 1 cm 247 84.8 0.20 (0.14-0.29)   0.42 (0.28-0.64)   
VTE    <0.0001  0.29 
No 935 54.9 1  1  
Yes 203 32.4 1.80 (1.44-2.24)   1.16 (0.88-1.52)   
Stage-specific 
histologic type 
      
Advanced  
HG-SOC 
701 37.5 1  1  
Advanced  
OCCC 
106 28.2 1.71 (1.30-2.24) <0.0001 2.19 (1.62-2.97) <0.0001 
Early-stage  
HG-SOC 
67 81.3 0.20 (0.11-0.37) <0.0001 0.31 (0.15-0.64) 0.001 
Early-stage  
OCCC 
264 89.5 0.11 (0.07-0.17) <0.0001 0.27 (0.16-0.45) <0.0001 
 
† The log-rank test was used for univariate analysis and Cox proportional hazards regression 
modeling was used for multivariate analysis.  
* Platelet count ≥400 ×109/L. 
Abbreviations: HR, hazard ratio; CI, confidence interval; CA-125, cancer antigen 125; VTE, venous 
thromboembolism; HG-SOC, high-grade serous ovarian cancer; OCCC, ovarian clear cell 
carcinoma. 
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Table S6. Factors influencing overall survival (OS) after recurrence or progression in sub-
analysis (n = 681) 
Variable 
  
No. 
 2-year OS 
rate after 
recurrence, % 
Univariate Multivariate 
HR (95%CI) P-value
†
 HR (95%CI) P-value
†
 
Age    0.12  0.31 
<60 years 331 43.2 1  1  
≥60 years 350 35.8 1.18 (0.96-1.44)   1.17 (0.86-1.59)   
CA-125 levels*    0.001  0.001 
≤35 IU/L 90 58.2 1  1  
>35 IU/L 282 38.1 1.94 (1.30-2.89)   2.00 (1.31-3.04)   
Thrombocytosis*    0.002  0.021 
No 305 20.5 1  1  
Yes 58 11.3 1.75 (1.24-2.48)   1.55 (1.07-2.24)   
VTE    0.036  0.65 
No 528 42.4 1  1  
Yes 153 31.4 1.28 (1.02-1.62)   1.08 (0.77-1.52)   
Stage-specific 
histologic subtype 
      
Advanced  
HG-SOC 
546 43.3 1  1  
Advanced 
OCCC 
80 16.1 2.20 (1.67-2.92) <0.0001 2.73 (1.89-3.96) <0.0001 
Early-stage  
HG-SOC 
22 66.3 0.58 (0.30-1.13) 0.11 0.97 (0.46-2.01) 0.92 
Early-stage 
OCCC 
33 31.1 1.12 (0.70-1.78) 0.64 2.00 (1.19-3.35) 0.009 
 
† The log-rank test was used for univariate analysis and Cox proportional hazards regression 
modeling was used for multivariate analysis.  
* CA-125 and platelet counts were measured at the time of first recurrence or progression of 
disease. 
Abbreviations: HR, hazard ratio; CI, confidence interval; CA-125, cancer antigen 125; VTE, venous 
thromboembolism; HG-SOC, high-grade serous ovarian cancer; OCCC, ovarian clear cell 
carcinoma.
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Supplemental Figure S1. Proposed schema for the role of interleukin-6 (IL-6) in ovarian clear 
cell carcinoma. The dashed line indicates the clinical manifestation of venous thromboembolism 
(VTE) in advanced ovarian clear cell carcinoma. Abbreviations: HIF1, hypoxia-inducible factor 1; 
STAT3, signal transducer and activator of transcription 3; PIK3CA, phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit alpha. 
 
 
